Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
| Revenue (TTM) | $20.61B |
| Gross Profit (TTM) | $14.21B |
| EBITDA | $5.50B |
| Operating Margin | 20.60% |
| Return on Equity | 14.70% |
| Return on Assets | 6.07% |
| Revenue/Share (TTM) | $13.91 |
| Book Value | $17.40 |
| Price-to-Book | 2.62 |
| Price-to-Sales (TTM) | 3.32 |
| EV/Revenue | 3.746 |
| EV/EBITDA | 14.06 |
| Quarterly Earnings Growth (YoY) | 100.00% |
| Quarterly Revenue Growth (YoY) | 11.60% |
| Shares Outstanding | $1.49B |
| Float | $1.48B |
| % Insiders | 0.23% |
| % Institutions | 93.77% |
Volatility is currently contracting
Boston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competitive pressure in U.S. electrophysiology.
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion.
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets.
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
Boston Scientific (BSX) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.75 per share a year ago.
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period.
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BSX and any ticker you trade — then tracks every position and per-strategy win rate.
